The LYCRA Company Launches LYCRA EnviroFit™ Fiber at INDEX™ 23
13.4.2023 12:00:00 EEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the personal care and apparel industries, is exhibiting its newest fiber innovations for hygiene and personal care products at INDEX™ 23, the world’s leading nonwovens exhibition, which takes place at Palexpo in Geneva, Switzerland, April 18 – 21.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005005/en/
The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber for personal care products at INDEX™ 23, April 18 – 21. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping to conserve resources without compromising product performance. (Photo: Business Wire)
At the trade show, The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber, one of the many fibers that the company has developed as part of its Planet Agenda sustainability platform. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping conserve resources without compromising product performance.
“We are thrilled to introduce LYCRA EnviroFit™ fiber, which reduces fiber weight while maintaining the overall quality and performance that personal care products require,” said Scott Blackadar, president, personal care at The LYCRA Company. “Having less mass means fewer resources and less energy are consumed during diaper production. This fiber will appeal to manufacturers who want to significantly reduce their product’s environmental impact and help improve its carbon footprint.”
In addition to continuously improving its range of fibers for personal care products, The LYCRA Company also focuses on providing total solutions for the challenges its customers face. The company is offering two unique delivery technologies aimed at improving the spandex unwinding process and improving diaper line productivity that will also be promoted at the show.
Introducing Trio Loop Yarn Control
The LYCRA Company is showcasing the Trio Loop Technology at INDEX™ 23, the latest yarn control system from BTSR International S.p.A. Trio Loop Technology, in combination with MATRIXCUBE tension controlled plug-and-play unwinding systems, improves yarn tension control and adds more troubleshooting options to further improve diaper line productivity.
Distributing Knotter Type 093E
The LYCRA Company is also the exclusive global distributor of the new and improved Knotter Type 093E for diaper production. This breakthrough innovation by Mesdan S.p.A. offers manufacturers greater efficiency and reliability by eliminating manual knot tying and reducing machine stops.
“By offering these delivery technologies, we are demonstrating that we are a trusted and highly valued solution provider in the industry,” said Werner Hopstaken, global director, personal care at The LYCRA Company. “We are excited to offer our personal care customers these innovative products by BTSR and Mesdan and encourage them to contact us to learn more.”
Visit The LYCRA Company representatives at INDEX™ 23 stand number 2151 or visit this website to discover more benefits of these innovations.
About INDEX™ 23
INDEX™ 23 is the largest global trade show for the nonwovens market. Held every three years, it attracts thousands of visitors from over 100 countries in every region. In addition to its exhibit space, INDEX™ hosts free industry workshops, seminars, tutorials, and presentations during the show. For more information, visit indexnonwovens.com.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, marketing support, and LYCRA ONE™ marketplace. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
LYCRA EnviroFit™ is a trademark of The LYCRA Company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005005/en/
Contact information
Werner Hopstaken
werner.hopstaken@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom